# Biomissile

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomissile

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Total disclosed funding: $54M
- Latest round: Series B (May 18, 2023)
- Investors on record: 2

## About

Established in 2020 and based in Suzhou, China, Biomissile is a biopharmaceutical company that focuses on the development of innovative biomolecular drugs. The company's core team has more than 20 years of experience in the development of biologically innovative drugs. In May 2023, it raised CNY 200 million in series B funding led by new investor Kequan Fund, with participation from another returning investor Fosun Health Capital. The company has completed 2 rounds of funding as of 2023.

The company has established several fully human rapid antibody discovery and optimization platforms, including a fully human nanobody (UDABTM) and a bispecific antibody platform (UDAB-MTM), as well as phage, yeast, and mammalian cell display platforms.

## Funding rounds

- Series B, May 18, 2023, $29M — Fosun Health Capital, Kequan Fund
- Series A, Sep 22, 2020, $25M — Fosun Health Capital

## Investors

- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series A, Series B
- Kequan Fund — Series B